BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 20089648)

  • 1. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.
    Fang X; Zhang S; Sun X; Li J; Sun T
    Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
    Publicover J; Ramsburg E; Rose JK
    J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    Rose NF; Roberts A; Buonocore L; Rose JK
    J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
    Kapadia SU; Simon ID; Rose JK
    Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
    Majid AM; Ezelle H; Shah S; Barber GN
    J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
    J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.
    Ahmed M; Marino TR; Puckett S; Kock ND; Lyles DS
    J Virol; 2008 Sep; 82(18):9273-7. PubMed ID: 18614644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
    Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
    J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.